The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

The Alliance for Pharmacy Compounding (APC), a trade organisation representing the compounding industry, has claimed that Novo Nordisk is "confusing the fact that the semaglutide molecule is ...

Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...

Novo Nordisk on Friday ... a weekly injection combining semaglutide, which is the active ingredient in Wegovy and mimics the gut hormone GLP-1, and a separate molecule called cagrilintide that ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

On Friday morning, Novo Nordisk unveiled the latest results from a clinical trial of CagriSema, an investigational drug ...

Its focus has previously been on two lead programmes, a peptide drug called EMB1 for cardiometabolic disease, and EMB2, a small-molecule ... Novo Nordisk's GLP-1 drug Wegovy (semaglutide).

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

As concerns around knockoffs of newer GLP-1 drugs like Ozempic and Wegovy take center stage, Novo Nordisk’s efforts ... of which are girded by the molecule semaglutide. In October, Novo asked ...